1. Mortality in Systemic Sclerosis–Associated Interstitial Lung Disease in Brazil
- Author
-
Cristiane Kayser, Sandra Maximiano Oliveira, Fernanda Godinho de Amorim, Juliana Silvatti, Cecilia Victoria Agapito Tito, and Lucas Victória de Oliveira Martins
- Subjects
medicine.medical_specialty ,Vital capacity ,Multivariate analysis ,behavioral disciplines and activities ,Scleroderma ,Rheumatology ,Internal medicine ,medicine ,Humans ,skin and connective tissue diseases ,Lung ,Cause of death ,Scleroderma, Systemic ,integumentary system ,business.industry ,Medical record ,Interstitial lung disease ,respiratory system ,medicine.disease ,respiratory tract diseases ,Cohort ,Observational study ,Lung Diseases, Interstitial ,business ,Brazil ,Follow-Up Studies - Abstract
OBJECTIVES The aim of this study was to identify risk factors associated with mortality in patients with systemic sclerosis (SSc), particularly those with interstitial lung disease (ILD), over a long-term follow-up in a large Brazilian SSc cohort. METHODS We conducted a medical records review study of 380 scleroderma patients from 1982 to 2019. Systemic sclerosis ILD was considered in those with evidence of ILD on chest high-resolution computed tomography (HRCT). Causes of death were determined. RESULTS Among the 380 SSc patients, SSc-ILD on chest HRCT was observed in 227 patients (59.7%). Seventy-two patients (18.9%) died during a mean follow-up of 7.2 years since the SSc diagnosis; among them, 57 (79.2%) had SSc-ILD, compared with 15 (20.8%) without SSc-ILD (p < 0.001). Of the 72 deaths, 51.4% were considered related to SSc, and ILD was the leading cause of death. The overall survival rates at 5, 10, and 15 years were 87.9%, 81.5%, and 74.9%, respectively. Kaplan-Meier analysis showed a significantly worse prognosis among patients with SSc-ILD than among those without ILD (p < 0.001). Among patients with SSc-ILD, disease duration of less than 4 years (p < 0.001), forced vital capacity
- Published
- 2021
- Full Text
- View/download PDF